vs
Ginkgo Bioworks Holdings, Inc.（DNA）与i3 Verticals, Inc.（IIIV）财务数据对比。点击上方公司名可切换其他公司
i3 Verticals, Inc.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.6倍（$52.7M vs $33.4M），i3 Verticals, Inc.同比增速更快（-14.6% vs -23.8%），i3 Verticals, Inc.自由现金流更多（$13.8M vs $-47.7M），过去两年i3 Verticals, Inc.的营收复合增速更高（-4.7% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
Prusa i3是捷克Prusa Research公司生产的熔融沉积成型3D打印机系列，以Original Prusa i3为注册商标推出，同时也是RepRap项目的组成部分。2016年该系列就被评为全球使用率最高的3D打印机，最早由Josef Průša在2012年完成设计，2015年正式推出商用套件版本，目前最新型号同时提供散件套件和原厂组装版本，具备性价比高、易操作的优势。
DNA vs IIIV — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $52.7M |
| 净利润 | — | $484.0K |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 3.1% |
| 净利率 | — | 0.9% |
| 营收同比 | -23.8% | -14.6% |
| 净利润同比 | — | -76.5% |
| 每股收益（稀释后） | $-1.41 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $33.4M | $52.7M | ||
| Q3 25 | $38.8M | $46.0M | ||
| Q2 25 | $49.6M | $51.9M | ||
| Q1 25 | $48.3M | $63.1M | ||
| Q4 24 | $43.8M | $52.2M | ||
| Q3 24 | $89.0M | $32.0M | ||
| Q2 24 | $56.2M | $46.2M | ||
| Q1 24 | $37.9M | $58.0M |
| Q4 25 | — | $484.0K | ||
| Q3 25 | $-80.8M | $3.1M | ||
| Q2 25 | $-60.3M | $12.9M | ||
| Q1 25 | $-91.0M | $-154.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-56.4M | $117.9M | ||
| Q2 24 | $-217.2M | $-7.5M | ||
| Q1 24 | $-165.9M | $1.9M |
| Q4 25 | -211.9% | 3.1% | ||
| Q3 25 | -231.8% | 3.2% | ||
| Q2 25 | -132.1% | -9.3% | ||
| Q1 25 | -184.1% | 8.0% | ||
| Q4 24 | -236.3% | 3.9% | ||
| Q3 24 | -62.0% | 10.6% | ||
| Q2 24 | -396.7% | -2.8% | ||
| Q1 24 | -469.1% | 3.4% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | -207.9% | 6.7% | ||
| Q2 25 | -121.6% | 24.8% | ||
| Q1 25 | -188.2% | -0.2% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | -63.3% | 368.2% | ||
| Q2 24 | -386.4% | -16.3% | ||
| Q1 24 | -437.3% | 3.2% |
| Q4 25 | $-1.41 | $0.02 | ||
| Q3 25 | $-1.45 | $0.14 | ||
| Q2 25 | $-1.10 | $0.50 | ||
| Q1 25 | $-1.68 | $0.00 | ||
| Q4 24 | $-1.91 | $0.08 | ||
| Q3 24 | $-1.08 | $4.93 | ||
| Q2 24 | $-4.23 | $-0.32 | ||
| Q1 24 | $-3.32 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $37.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $358.5M |
| 总资产 | $1.1B | $595.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $422.6M | $37.5M | ||
| Q3 25 | $495.5M | $66.7M | ||
| Q2 25 | $559.4M | $55.5M | ||
| Q1 25 | $325.3M | $7.7M | ||
| Q4 24 | $561.6M | $85.6M | ||
| Q3 24 | $616.2M | $86.5M | ||
| Q2 24 | $730.4M | $9.7M | ||
| Q1 24 | $840.4M | $3.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $26.2M | ||
| Q3 24 | — | $26.2M | ||
| Q2 24 | — | $374.1M | ||
| Q1 24 | — | $369.6M |
| Q4 25 | $508.6M | $358.5M | ||
| Q3 25 | $559.8M | $389.6M | ||
| Q2 25 | $613.0M | $383.3M | ||
| Q1 25 | $647.4M | $385.2M | ||
| Q4 24 | $716.1M | $375.0M | ||
| Q3 24 | $797.9M | $379.7M | ||
| Q2 24 | $833.1M | $249.7M | ||
| Q1 24 | $987.3M | $249.3M |
| Q4 25 | $1.1B | $595.9M | ||
| Q3 25 | $1.2B | $638.4M | ||
| Q2 25 | $1.2B | $623.3M | ||
| Q1 25 | $1.3B | $646.4M | ||
| Q4 24 | $1.4B | $726.2M | ||
| Q3 24 | $1.5B | $730.7M | ||
| Q2 24 | $1.6B | $861.7M | ||
| Q1 24 | $1.6B | $625.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $14.1M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $13.8M |
| 自由现金流率自由现金流/营收 | -142.8% | 26.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 29.18× |
| 过去12个月自由现金流最近4个季度 | — | $6.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-47.7M | $14.1M | ||
| Q3 25 | $-31.6M | $14.0M | ||
| Q2 25 | $-40.3M | $7.4M | ||
| Q1 25 | $-51.5M | $-27.1M | ||
| Q4 24 | $-42.4M | $11.5M | ||
| Q3 24 | $-103.5M | $15.1M | ||
| Q2 24 | $-84.4M | $8.1M | ||
| Q1 24 | $-89.3M | $10.7M |
| Q4 25 | $-47.7M | $13.8M | ||
| Q3 25 | — | $13.5M | ||
| Q2 25 | $-40.3M | $6.8M | ||
| Q1 25 | $-59.1M | $-27.6M | ||
| Q4 24 | $-56.1M | $11.0M | ||
| Q3 24 | $-118.6M | $14.6M | ||
| Q2 24 | $-111.4M | $7.2M | ||
| Q1 24 | $-96.0M | $9.9M |
| Q4 25 | -142.8% | 26.2% | ||
| Q3 25 | — | 29.5% | ||
| Q2 25 | -81.2% | 13.1% | ||
| Q1 25 | -122.4% | -43.8% | ||
| Q4 24 | -128.0% | 21.1% | ||
| Q3 24 | -133.2% | 45.6% | ||
| Q2 24 | -198.2% | 15.6% | ||
| Q1 24 | -252.9% | 17.1% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 15.8% | 0.8% | ||
| Q4 24 | 31.3% | 0.9% | ||
| Q3 24 | 16.9% | 1.7% | ||
| Q2 24 | 48.1% | 1.9% | ||
| Q1 24 | 17.7% | 1.4% |
| Q4 25 | — | 29.18× | ||
| Q3 25 | — | 4.52× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.59× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
IIIV
| License And Service | $35.7M | 68% |
| Proprietary Payments Revenue | $14.5M | 27% |
| Other Revenue | $2.5M | 5% |
